Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
| Autor: | Cheson, Bruce D *, Bartlett, Nancy L, LaPlant, Betsy, Lee, Hun J, Advani, Ranjana J, Christian, Beth, Diefenbach, Catherine S, Feldman, Tatyana A, Ansell, Stephen M |
|---|---|
| Zdroj: | In The Lancet Haematology November 2020 7(11):e808-e815 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|